GlassScriptPhysician profile
Suneetha Jasty
NPI 1881957090
$3,338.50
in general payments reported to CMS, 2019-2025
22 companies · $774 in 2025
The $774 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2021: $539 · 2022: $706 · 2023: $146 · 2024: $52.33 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $382.22 | 2021-2025 | Benlysta |
| Amgen INC. | $370.19 | 2019-2025 | Otezla, Evenity, Prolia |
| Janssen Biotech, INC. | $223.36 | 2019-2025 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $212.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $196.33 | 2021-2022 | |
| Ucb, INC. | $168.04 | 2019-2025 | Bimzelx |
| Celgene Corporation | $152.86 | 2019 | |
| Pfizer INC. | $133.52 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $119.50 | 2021 | |
| Genzyme Corporation | $118.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.98 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $98.44 | 2019-2025 | Orencia |
| Radius Health, INC. | $53.92 | 2019-2025 | Tymlos |
| Mallinckrodt Enterprises LLC | $53.66 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $50.72 | 2025 | Jubbonti |
| Octapharma USA, INC. | $49.05 | 2021 | |
| Lilly USA, LLC | $44.80 | 2021-2025 | Taltz |
| Organon LLC | $21.78 | 2025 | Hadlima |
| Biocon Biologics INC | $19.82 | 2025 | Yesintek |
| Pacira Therapeutics, INC. | $17.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.14 | 2025 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneetha Jasty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.